18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the Catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed.

          Related collections

          Author and article information

          Journal
          Autoimmun Rev
          Autoimmunity reviews
          1873-0183
          1568-9972
          Sep 2013
          : 12
          : 11
          Affiliations
          [1 ] Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Catalonia, Spain.
          Article
          S1568-9972(13)00111-0
          10.1016/j.autrev.2013.05.004
          23777822
          17ddf9c3-d5c2-46ec-b61a-c4cfec83effb
          Copyright © 2013 Elsevier B.V. All rights reserved.
          History

          Anti-CD20,Catastrophic antiphospholipid syndrome,Refractory,Rituximab

          Comments

          Comment on this article